C ardiovascular disease (CVD) is the leading cause of morbidity and mortality among women in developed countries, and elevated blood pressure (BP) is a leading contributor to this phenomenon. 1, 2 Although the benefits of lowering increased BP in reducing CVD morbidity and mortality in the population as a whole have been well established, until recently, data documenting the specific benefits of antihypertensive treatment in reducing cardiovascular (CV) complications of hypertension in women were not available.
C ardiovascular disease (CVD) is the leading cause of morbidity and mortality among women in developed countries, and elevated blood pressure (BP) is a leading contributor to this phenomenon. 1, 2 Although the benefits of lowering increased BP in reducing CVD morbidity and mortality in the population as a whole have been well established, until recently, data documenting the specific benefits of antihypertensive treatment in reducing cardiovascular (CV) complications of hypertension in women were not available. 3 Furthermore, before the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), CVD outcome data comparing the effects of nondiuretic-based antihypertensive therapy (ie, angiotensinconverting enzyme [ACE] inhibitors or calcium channel blockers) to diuretic therapy in women were absent. This is particularly significant because hypertension is highly prevalent, difficult to control, and associated with a high incidence of CVD complications in older women, the population that was enrolled in ALLHAT. [4] [5] [6] Data from the Framingham Heart Study showed an age-related decline in BP control rates that was more pronounced in women than in men. 6 Among the oldest participants with hypertension, only 23% of women (versus 38% of men) were controlled to BP <140/90 mm Hg. A cross-sectional analysis of data from the 2005 National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey also showed that among patients with hypertension, women were less likely than men to meet BP control targets. 7 The sex disparity was particularly large in the elderly, where the odds ratio of having controlled BP in women compared with men was 0.62 (95% confidence interval [CI] , 0.45-0.85). It is not clear from these studies whether the sex disparity in BP control rates in elderly patients was related to true treatment resistance among women because of biological factors or to incompletely understood characteristics of the healthcare delivery system.
ALLHAT was a randomized, double-blind, National Heart, Lung, and Blood Institute-sponsored trial that recruited 42 418 participants and compared an ACE inhibitor (lisinopril), an α blocker (doxazosin), and a calcium channel blocker (amlodipine), each with a diuretic (chlorthalidone). 8, 9 ALLHAT reported that chlorthalidone was not surpassed in preventing coronary heart disease (CHD) compared with doxazosin, lisinopril, or amlodipine; was more effective than these agents in preventing heart failure (HF); and was more effective than doxazosin or lisinopril in preventing stroke and a composite of CVD outcomes. 10 Results for the doxazosin arm, which was terminated early, have been reported in several articles, and are not included here.
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The ALLHAT cohort included 47% women with a mean age of 67 years at enrollment and prespecified subgroups in the trial included women and men. 8, 9 Thus, ALLHAT offers an excellent opportunity to compare the effects on CVD outcomes of representatives of the newer classes of antihypertensive agents versus those of the diuretic chlorthalidone in a large population of older, higher risk women. In addition, we tested whether 5 years of in-trial randomized antihypertensive treatment resulted in persistence or de novo development of mortality and morbidity differences during extended followup of 8 to 13 years. [18] [19] [20] [21] The primary outcome for the long-term (in-trial plus post-trial) analyses was CVD mortality. This report details the results of the in-trial and post-trial analyses by sex. In particular, we now examine in detail the interactions of sex and treatment in determining CVD outcomes with emphasis on treatment effects in women.
Methods
The rationale and design of ALLHAT have been presented elsewhere, 7 and more extensive details are in the online-only Data Supplement. 8 Briefly, participants were women and men age ≥55 years with hypertension and at least 1 additional risk factor for CHD events. 8, 9 All participants provided written informed consent, and all centers obtained institutional review board approval. The study adhered to the principles of the Declaration of Helsinki and Title 45, US Code of Federal Regulations, Part 46, Protection of Human Subjects.
Participants (n = 33 357) were assigned by a computer-generated randomization schedule to chlorthalidone, amlodipine, or lisinopril in a ratio of 1.7:1:1, respectively. Goal BP in each randomized group was <140/90 mm Hg achieved by titrating the assigned study drug (step 1) and adding open-label agents (step 2 or 3) when necessary. Method of BP measurement is detailed elsewhere. 22 The primary outcome was a composite of fatal CHD or nonfatal myocardial infarction. [8] [9] [10] Four major prespecified secondary outcomes were (1) all-cause mortality; (2) fatal and nonfatal stroke; (3) combined CHD (the primary outcome, coronary revascularization, hospitalized angina); and (4) combined CVD (combined CHD, stroke, other treated angina, HF [fatal, hospitalized, or treated nonhospitalized], and peripheral arterial disease). Individual components of the combined outcomes also were examined. Other prespecified secondary outcomes included cancer and end-stage renal disease (ESRD; dialysis, renal transplant, or death). For the in-trial plus post-trial periods, the primary outcome was CV mortality, and secondary outcomes were mortality, stroke, CHD, HF, CVD, and ESRD. For details on the use of national databases, see online-only Data Supplement and Cushman et al. 18 For the post-trial period, data are not available on medications, serum chemistries, or BP levels.
Statistical Analyses
Baseline characteristics and intermediate outcomes were compared across treatments within each sex subgroup using analysis of variance for continuous covariates and contingency table analyses for categorical data. Data were analyzed according to participants' randomized treatment assignments regardless of their subsequent medications (ie, intention-to-treat analysis). Six-year cumulative event rates for the in-trial data and 10-year event rates for the post-trial data were calculated using the Kaplan-Meier procedure. Cox proportional hazards models were used to obtain hazard ratios (HRs) and 95% CIs for time-to-event outcomes, and included the participant's entire trial experience for both the in-trial and the combined in-trial plus post-trial periods. Heterogeneity of treatment effects across sex subgroups was examined by testing for treatment × sex interaction with the proportional hazards model using P<0.05. Given the many multivariate, subgroup, and interaction analyses performed, statistical significance at the .05 level should be interpreted with caution. Stata version 11 (Stata Corp, College Station, TX) was used for all analyses. Further details are provided in the major ALLHAT outcomes article, 10 the ALLHAT extension article, 18 and the ALLHAT extension protocol (www.allhat.org). (Figure 1) shows the number of participants who entered the trial and their status at the end of the in-trial period (March, 2002) by sex. There were 17 719 men and 15 638 women randomized into ALLHAT.
Results

A consort diagram
Baseline Characteristics
Women accounted for 47% of the ALLHAT population (Table 1) . They were slightly older (by ½ year), were more likely to be black (41% versus 30%) or Hispanic (19% versus 13%), and had lower educational attainment. Although there was little difference by sex in percentages of those aged 55 to 64 years, there were fewer women than men among those aged 65 to 80 years (49% versus 53%), whereas there were more women among those aged 80 years and older (8.4% versus 4.8%). The percentage on treatment at entry was similar in men 24 .1%). The prevalence of atrial fibrillation at baseline was low and about half that in men (0.7% versus 1.3%). There were no significant differences across the 3 drug treatment groups in baseline BP or other baseline characteristics within either sex subgroup, except for (1) history of myocardial infarction or stroke in women, which was lower in the lisinopril group (16.6%) than in the chlorthalidone and amlodipine groups (18.5% and 18.8%, respectively); (2) history of CHD in men, lower in the amlodipine (29.7%) than chlorthalidone group (31.5%); and (3) estimated glomerular filtration rate in men, which was lower in chlorthalidone group (78.3) than in amlodipine group (79.1).
During the post-trial period, we were able to passively follow 17 411 men and 15 393 women for mortality status and 9537 men and 12 086 women for morbidity status ( Figure S1 in the online-only Data Supplement). The larger differential between the sexes for morbidity status occurred because of the lack of follow-up for participants from the Department of Veterans' Affairs, who were mostly male (Cushman et al 18 for details).
Intermediate Outcomes
BP decreased substantially during the first year of the study and showed modest further decreases during subsequent years in both sexes in all treatment groups, although the decreases in systolic BP were slightly less in women than in men across treatment groups ( Figure 2 and Table 2 ). Together with higher baseline BPs, this resulted in significantly higher systolic BPs in women than in men during the study. Diastolic BPs showed only minor differences between sexes. In women, the mean reduction in systolic BP from baseline was 2 to 3 mm Hg greater with chlorthalidone than with lisinopril and 0.4 to 1 mm Hg greater with chlorthalidone than with amlodipine. The mean attained systolic BP in women was 2 to 3 mm Hg lower on chlorthalidone versus lisinopril, and differed by <1 mm Hg on chlorthalidone versus amlodipine. Treatment-related differences were smaller in men: follow-up systolic BPs were 1.3 to 1.5 mm Hg lower on chlorthalidone than on either amlodipine or lisinopril. Follow-up diastolic BPs in men were similar in all 3 treatment groups. Although BP control rates were lower with lisinopril compared with chlorthalidone or amlodipine, >60% of participants were controlled to <140/90 mm Hg at year 4, and mean BP was <140/90 mm Hg in both sex subgroups. The percentage of participants with controlled BP (<140/90 mm Hg) was lower in women than in men by 1% to 4% at baseline across treatment groups, and this difference increased to 6% in the chlorthalidone and lisinopril groups, but decreased to 2% in the amlodipine group after 4 years of follow-up. BP control rates at year 4 were lowest with lisinopril in both sex subgroups; control rates with chlorthalidone and amlodipine were similar in women, but greater with chlorthalidone than amlodipine in men.
Prevalence of diabetes mellitus based on examining only fasting blood glucose levels at baseline (rather than glucose ALLHAT indicates Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CHD, coronary heart disease; CVD, cardiovascular diseases; DBP, diastolic blood pressure; DM, diabetes mellitus; GFR, glomerular filtration rat; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVH, left ventricular hypertrophy; and SBP, systolic blood pressure.
*All results are presented as percentages of the number of participants randomized to the treatment groups unless otherwise indicated. †Ethnicity is by self-report ‡Diabetes mellitus = history of diabetes mellitus at baseline or fasting glucose ≥126 mg/dL §Impaired fasting glucose = no history and baseline fasting glucose is 110 to 125 mg/dL inclusive ¶Normoglycemic = not classified as impaired fasting glucose, no history of diabetes mellitus and at least one fasting glucose or nonfasting glucose is <110 mg/dL. #Participants randomized to the ALLHAT Lipid Trial, an open-label substudy of pravastatin vs usual care in those participants with elevated cholesterol **Other atherosclerotic CVD is any of history of angina pectoris; history of intermittent claudication, gangrene, or ischemic ulcers; history of transient ischemic attack; coronary, peripheral vascular, or carotid stenosis ≥50% documented by angiography or Doppler studies; ischemic heart disease documented by reversible or fixed ischemia on stress thallium or dipyridamole thallium.
† †ST-T wave is any major ST segment depression or T-wave inversion on any ECG in the past 2 y. ST depression ≥1 mm for ≥1 min on exercise testing or Holter monitoring; reversible wall motion abnormality on stress echocardiogram; ankle-arm index <0.9; abdominal aortic aneurysm detected by ultrasonography, computed tomography scan, or radiograph; carotid or femoral bruits.
by guest on August 30, 2017 http://hyper.ahajournals.org/ Downloaded from levels or history of diabetes mellitus as in Table 1 ) was higher in women than men, 30.7% versus 28.0% (Table 2) . 23 During follow-up, fasting blood glucose increased the least in the lisinopril arm, and the most in the chlorthalidone arm in both sex subgroups ( Table 2 ). The percentage of participants with fasting blood glucose >126 mg/dL at 2 and 4 years of follow-up increased by 2% to 5% with chlorthalidone, increased by 1% to 2% with amlodipine, and changed by between +1% and −3% with lisinopril in both sex groups. During follow-up, changes in serum K + , serum cholesterol, and serum creatinine were similar to what has been reported previously in both sexes (data not shown). 10 For the post-trial period, data are not available on glucose, potassium, cholesterol or creatinine levels, or BP.
In-Trial Primary and Secondary Outcomes
Six-year event rates for the primary outcome of nonfatal myocardial infarction and fatal CHD were lower in women than in men, 9.1 versus 13.9 per 100 participants (Tables 3 and 4) . Between treatments, no significant differences were noted in either sex subgroup. Rates for the secondary end points of allcause mortality, combined CHD, combined CVD, stroke, HF (treated/fatal/hospitalized), and cancer were all lower in women. Rates for components of the secondary end points, including angina, coronary revascularization, and peripheral arterial disease, were also lower in women, whereas rates for hospitalized/ fatal HF and ESRD were similar in women and men.
Between treatments, no significant differences were observed for all-cause mortality or its subcomponents, CV or combined CHD mortality, in either sex ( Figure 3A and 3B) . In women, stroke mortality rates tended to be lower (HR=0.86; P=0.45, for amlodipine versus chlorthalidone) and higher (HR=1.38; P=0.07, for lisinopril versus chlorthalidone). In men, these differences were smaller and also not statistically significant and there were no significant sex-treatment interactions (P>0.36). Combined CVD and HF (treated/fatal/hospitalized) were significantly increased in the lisinopril versus chlorthalidone arms in both women and men, whereas both HF outcomes were significantly increased in the amlodipine versus chlorthalidone arms. Stroke was significantly increased for women only in the lisinopril versus chlorthalidone comparison. There were no significant treatment sex interactions. Individual components of the combined CVD end point did not differ by sex. Regarding other secondary outcomes, rates for cancer or ESRD were not different in the amlodipine and lisinopril arms versus the chlorthalidone arm for either women or men.
Extension Results
No significant differences were observed in CV mortality for amlodipine (HR, 1.01; 95% CI, 0.93-1.10) or lisinopril (HR, 0.96; CI, 0.88-1.05), each compared with chlorthalidone, overall, or for men or women (Table S1 and Figure S2 ). The only significant differences in secondary outcomes were for hospitalized and fatal HF, which was higher with amlodipine (HR, 1.12; CI, 1.02-1.22), and stroke mortality, which was higher with lisinopril (HR, 1.20; CI, 1.01-1.41), each compared with chlorthalidone. Although men had a significantly higher HF risk (HR=1.17; P=0.03), there were no significant interactions by sex.
The only significant treatment sex interaction noted was for cancer mortality for amlodipine versus chlorthalidone. For women, the HR was 1.20, 95% CI (1.02-1.40); for men, it was 0.93, 95% CI (0.82-1.05), P for interactions =0.01. With regard to comparison of rates by sex, men had higher overall total, CVD, and CHD 10-year mortality rates than women, whereas the stroke and HF 10-year morality rates were similar, overall, and within each treatment group. For combined fatal/nonfatal outcomes, men had higher 10-year rates of CHD, CVD, stroke, cancer, and ESRD, but lower 10-year rates for HF.
Discussion
Subgroup analyses of ALLHAT extend the findings of this trial and those of other studies by confirming the consistency of the results in both sexes. 10, [24] [25] [26] [27] [28] In ALLHAT, no differences in CVD outcomes by sex were detected for the in-trial or extension periods.
For the in-trial period, there were significantly higher rates of HF, stroke, and combined CVD for lisinopril compared with chlorthalidone, and significantly higher rates of HF for amlodipine compared with chlorthalidone. These findings did not persist through the extension period with the exception of the HF result for amlodipine versus chlorthalidone. 18 Though men had a significant 17% increased risk for amlodipine versus chlorthalidone, this was not significantly different from the result for women. Also, the finding of significantly higher stroke mortality during the extension period overall (HR, 1.20; CI, 1.10-14.1) for lisinopril versus chlorthalidone 18 did not differ significantly by sex. These results could be consistent with many other post-trial results, wherein the medications used, including the use of diuretics, likely became more similar across the randomized groups, or could be attributable to chance. *The number of participants with fasting glucose values is smaller than the numbers for the other measurements because the participants frequently arrived nonfasting, were asked to return fasting, and did not. The mean at baseline was also calculated for fasting glucose for only those participants who had a fasting glucose at year-2 follow-up. This is to make it easier for the reader to understand the mean changes, which are calculated only for participants with measurements at both time points.
†The mean changes are calculated using only those participants who have both a value at baseline and a value at the indicated year of follow-up. All other means are calculated for all participants at the designated time point. In a previous summary of the ALLHAT findings, 29 it was noted that BP differences may account for some but not all of the advantages seen with chlorthalidone. ALLHAT has reported analyses using achieved BP levels as time-dependent covariates in a Cox proportional hazard regression model showing that after adjustment for BP, the differences in risk of stroke and HF between treatment arms remain statistically significant, with only slight reduction in the HRs. 10, 14, 17, 30 Also, in this previous summary, 29 it was noted that at doses equivalent to that used in ALLHAT (chlorthalidone, average of 20 mg/d), it is likely that attributes of chlorthalidone extend to the class of thiazide and thiazide-type diuretics.
There was 1 significant treatment by sex interaction for the extended follow-up for cancer mortality (P=0.01 for interaction) for amlodipine versus chlorthalidone; women had an HR=1.20 (95%CI, 1.02-1.40; P=0.02), whereas men had an HR=0.93 (95% CI, 0.82-1.05; P=0.26). For the in-trial period, the results were similar-significant treatment × sex interaction (P=0.03 for interaction) for amlodipine versus chlorthalidone-women had an HR=1.19 (95% CI, 0.93-1.51; P=0.16), whereas men had an HR=0.82 (0.68-0.97; P=0.02). Given the many analyses performed, this may just be the play of chance.
These findings are consistent with results of a prospectively designed overview by the Blood Pressure Lowering Treatment Trialists' Collaboration of 31 randomized controlled trials of antihypertensive treatment with CVD outcomes that included 87 349 women and 103 268 men. 3 The collaboration, which included ALLHAT, tested whether there were important differences between sexes in the effects of different BP-lowering regimens. 3 Separate overviews were carried out for trials comparing active agents with placebo, more intensive with less intensive BP-lowering regimens, and 1 active agent with another. For all treatment comparisons, mean baseline BPs were slightly higher for women compared with men, but achieved BP reductions were comparable in both sexes. There was no evidence of a difference in the effects of BP-lowering treatment regimens between women and men for any CVD outcome except stroke. For stroke, there was some evidence that women, but not men, derive greater benefit from calcium channel blocker-based regimens than ACE inhibitor-based regimens. Evidence for this interaction was of borderline (P=0.05) statistical significance and, in view of the large number (42) of subgroup analyses made in the study, was attributed by the authors to chance. Overall, there was no evidence that women and men derived different levels of outcome benefit from BP reduction or that regimens based on different drug classes were more effective in one sex than the other. On the basis of these observations, the authors concluded that a patient's sex should not influence decisions about the need for BP-lowering therapy, the magnitude of BP reduction to be sought, or the selection of drug class.
These findings reinforce the conclusions of earlier overviews of aggregated data from randomized trials that compared active treatment with placebo or less systematically treated controls and reported results by sex.
31- 33 The earlier analyses concluded that treatment effects (as assessed by HRs) on morbidity and mortality did not differ between women and men. Although absolute benefit of treatment did differ between sexes for some outcomes (eg, greater for CHD and mortality in men) but not others (eg, stroke), the sex differences in absolute benefit were entirely attributable to differences in underlying risk. With regard to choice of first-step drugs, early trial evidence suggested no significant differences in major outcomes between diuretic-based and β-blockerbased treatment in either sex. Other outcome trials of BP treatment that reported results by sex confirm the ALLHAT findings. With regard to calcium channel blocker-based treatment, the placebo-controlled Systolic Hypertension in Europe trial reported no interaction by sex for either stroke or cardiac outcomes, 34 and 1 direct comparator trial, the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial 25 reported no sex difference in relative risks for the primary composite CV outcome in the study as a whole, which were near unity, or between treatment arms (verapamil versus β-blocker or diuretic). A prespecified subgroup analysis from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial found a relative excess of the primary composite CV end point with valsartan-based compared with amlodipine-based treatment in women but not in men. 35, 36 Much of this outcome benefit was attributed to greater BP reduction with amlodipine in women. However, the authors questioned whether there is a genuine sex difference in the cardiac protection afforded by the amlodipine-based versus valsartan-based treatment because the trend toward less HF in valsartan-treated patients was significant only in men.
The results of ALLHAT differ from those of a smaller trial carried out in a less diverse population in which fewer events were reported. The Australian National Blood Pressure-2 (ANBP-2) trial showed a lack of benefit of ACE inhibitor (enalapril)-based treatment compared with diuretic-based treatment in women, but not in men. 37 There was a nonsignificant interaction by sex in the context of an overall marginally significant difference (P=0.05) favoring the ACE inhibitor for all CV events/total mortality. Only 524 events were observed in women in ANBP-2, suggesting that the apparent lack of benefit of ACE inhibitor treatment reflected inadequate power to detect a beneficial effect of renin-angiotensin-aldosterone system blockade in hypertensive women, in whom event rates are lower than in men. The different results may also reflect differences in baseline characteristics of the populations included in ANBP-2 compared with ALLHAT. ANBP-2 included an older population with higher baseline systolic and diastolic BPs and lower prevalence of CHD, cerebrovascular disease, diabetes mellitus, and smoking.
Perspectives
The similarity of the treatment effects in ALLHAT by sex is robust because of the large sample size equally distributed between men and women. The ALLHAT conclusion reported for the whole cohort that neither lisinopril nor amlodipine is superior to chlorthalidone for initial therapy of hypertension also applies to the prespecified subgroups defined by sex. These drugs did not surpass the diuretic chlorthalidone in lowering BP, tolerability, or in preventing major clinical complications of hypertension.
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Extended Follow-up Outcomes: Definitions and Determination
Mortality Only Endpoints
Mortality data were available during both in-trial and post-trial periods for the entire cohort except for Canadian participants (n= 553, due to lack of availability of necessary identifying information) (Figure 1) . In-trial deaths were ascertained by investigators and confirmed by death certificates, and posttrial deaths, from NDI and SSA. In-trial causes of death were determined by investigators. When the cause of death was reported as unknown, we used the NDI Plus database, which also provided causespecific mortality for the post-trial period. Data from NDI and SSA used Social Security number, name, date of birth, and sex (NDI only) as matching criteria.
CVD mortality (death due to CHD, stroke, HF, or other CVD) was designated a priori as the primary endpoint. Total mortality and categories of death were prespecified and assessed as important secondary outcomes (see research protocol at www.allhat.org).
A death identified through NDI or SSA was verified at the ALLHAT Clinical Trials Center (CTC) after receipt and review of a death certificate from the state or other jurisdiction. Of 6492 death certificates requested for the groups compared herein, 6488 (99.9%) were received, and 6367 (98.1% of those received) were determined to be for an ALLHAT participant. Death certificates were not obtainable for 4 deaths; these deaths and their reported causes were included in the main analyses, as the matching algorithm had been demonstrated to be highly reliable. Causes of death (ICD-10 coding) from NDI Plus were collapsed into 11 categories (see research protocol at www.allhat.org). These were initally provided under the International Classification of Diseases (ICD) 9 th revision; for deaths occurring in 1999 forward, the ICD-10 th revision. The World Health Organization (WHO)'s Two-way Translator for the Ninth and Tenth Revisions (1997) was used to convert ICD-10 codes to ICD-9.
Fatal and Nonfatal Endpoints
Hospitalization data were available for both in-trial and post-trial periods for the majority of participants. During the in-trial period, events were ascertained and classified by investigators and confirmed by the ALLHAT CTC based on discharge summaries. Unlike previous reports from ALLHAT, in-trial ESRD events (chronic dialysis or kidney transplant) were ascertained from the United States Renal Data System (USRDS). During the post-trial period, nonfatal events were ascertained from the Centers for Medicare and Medicaid Services (CMS [formerly HCFA]) and the USRDS. Events identified through CMS data were classified using the provided ICD-9 codes from those sources.
During the post-trial period, nonfatal outcome data, except for ESRD, are only available for participants from non-VA U.S. clinical centers who have valid Medicare or Social Security numbers (65% of all participants), due to lack of access for administrative reasons. The following fatal/non-fatal composites were prespecified as secondary endpoints: CVD (CVD death or hospitalized non-fatal MI, stroke, or HF), CHD (CHD death or hospitalized non-fatal MI), stroke (fatal or non-fatal hospitalized), HF (fatal or non-fatal hospitalized), and ESRD.
Details on how the databases were used to identify events are noted in our online protocol (see www.allhat.org). For the post-trial period, data are not available on medications, BP levels, outpatient morbidity, or laboratory values. 
